Serum levels of C1M, a biochemical marker of type I collagen degradation, may predict progression of total joint damage in ...

Pfizer and Novo Nordisk have underperformed the market over the past year. Pharmaceutical giants Pfizer (NYSE: PFE) and Novo ...

BioNTech's COVID-19 vaccine on one's eye, which could lead an indivual to permanent vision loss. Read on... TheHealthSite.com ...

New York City’s housing shortage may find an unlikely hero in its glut of underused office buildings, according to Brad ...

While no vision loss was noted, researchers observed slight corneal thickening and decreased endothelial cell count, ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

A new genetic test, based on data from more than five million people, can identify people at risk of severe obesity. The test can be performed on children before their genetic risk starts to shape ...

Researchers looked at how the vaccine affected patients' corneas - the clear front part of the eye that allows light to come ...

Global companies have been hit with a brutal $320 billion in lost profit since 2017, and it has nothing to do with bad ...

The portfolio strategy team at Goldman Sachs ranks the 11 sectors in the S&P 500 index by absolute and relative ...

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness ...

The FDA has approved once-monthly dosing of Elrexfio (elranatamab-bcmm) for certain patients with relapsed or refractory multiple myeloma.